Consensus on the clinical use of myeloid growth factors

Current Opinion in Hematology

Volumn 3, Issue 3, 1996, Pages 241-246

  Boogaerts, Marc A ^a   Demuynck, Hilde M ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; COLONY STIMULATING FACTOR; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEMOPOIETIC GROWTH FACTOR;

AGRANULOCYTOSIS; ALLOGENIC BONE MARROW TRANSPLANTATION; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BONE MARROW TRANSPLANTATION; CANCER CHEMOTHERAPY; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; HEMATOPOIESIS; HUMAN; INFECTION; INTRAVENOUS DRUG ADMINISTRATION; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; STEM CELL TRANSPLANTATION; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0030006329     PISSN: 10656251     EISSN: None     Source Type: Journal    
DOI: 10.1097/00062752-199603030-00013     Document Type: Review

References (53)

1. Boogaerts MA: Growth factors in haematology: prophylactic versus interventional use. Eur J Cancer 1994, 30:238-243.
2. Boogaerts M, Cavalli F, Cortes-Funes H, Gatell JM, Gianni AM, Khayat D, Levy Y, Link H: Granulocyte growth factors: achieving a consensus. Ann Oncol 1995, 6:237-44.
3. Americn Society of Clinical Oncology Recommendations for the Use of Hematopoietic Colony Stimulating Factors: Evidence-based, clinical practice guidelines. J Clin Oncol 1994, 12:2471-2508.
4. Frampton JE, Yarker YE, Goa KL: Lenograstim. A review of its pharmacological properties and therapeutic efficacy in neutropenia. Drugs 1995, 49:767-793.
5. Frampton JE, Lee CR, Faulds D: Filgrastim. A review of its pharmacological properties and therapeutic efficacy in neutropenia. Drugs 1994, 48:731-760.
6. Nissen C, Dalle Carbonare V, Moser Y, et al.: In vitro comparison of the biological potency of glycosylated versus nonglycosylated rG-CSF. Drug Invest 1994, 2:346-352.
7. Pettengel R, Gurney H, Radford JA, Deakin DP, James R, Willminson PM, Kane K, Bentley I, Crowther D: Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: a randomised controlled trial. Blood 1992, 80:1430-1436.
8. Crawford J, Ozer H, Stoller R, Johnson D, Lyman G, Tabbara I, Kris M, Grous I, Picozi V, Rausch G: Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 1991, 325:164-170.
9. Silvestri F, Velisig M, Fanin R, Virgolini L, Zaja F, Barillari G, Baccarani M: Granulocyte colony-stimulating factor (G-CSF) allows the delivery of effective doses of CHOP and CVP regimes in non-Hodgkin lymphomas. Leuk Lymphoma 1995, 16:465-470.
10. Vose JM, Armitage JO: Clinical applications of hematopoietic growth factors. J Clin Oncol 1995, 13:1023-1035.
11. Bonilla MA, Dale D, Zeidler C, Last L, Reiter A, Ruggiero M, Davis M, Koci B, Hammond W, Gillio A: Long-term safety of treatment with recombinant human granulocyte colony-stimulating factor (r-metHUG-CSF) in patients with severe congenltal neutropenias. Br J Haematol 1994, 88:723-730.
12. Chevalier B, Chollet P, Merrouche Y, Roche H, Fumoleau P, Kerbrat P, Genot JY, Fargeot P, Olivier JP, Fizames C: Lenograstim prevents morbidity from intensive induction chemotherapy in the treatment of inflammatory breast cancer. J Clin Oncol 1995, 13:1564-1571.
13. Dranitsaris G, Sutcliffe SB: Economic analysis of prophylactic G-CSF after mini-BEAM salvage chemotherapy for Hodgkin's and non-Hodgkin's lymphoma. Leuk Lymphoma 1995, 17:139-145.
14. Lind MJ, Gumbrell L, Cantwell BMJ, Millward MJ, Simmonds D, Proctor M, Chapman F, McCann E, Middleton I, Calvert AH: The use of granulocyte colony-stimulating factor to deliver four cycles of ifosfamide and epirubicin every 14 days in women with advanced or metastatic breast cancer. Br J Cancer 1995, 71:610-613.
15. Ottmann OG, Hoelzer D, Gracien E, Ganser A, Kelly K, Reutzel R, Lipp T, Busch FW, Schwonzen M, Heil G: Concomitant granulocyte colony-stimulating factor and induction chemoradiotherapy in adult acute lymphoblastic leukemia: a randomized phase III trial. Blood 1995, 86:444-450.
16. Woll PJ, Hodgetts J, Lomax L, Bildet F, Cour-Chabemaud V, Thatcher N: Can cytotoxic dose-intensity be increased by using granulocyte colony-stimulating factor? A randomized controlled trial of lenograstim in small-cell lung cancer. J Clin Oncol 1995, 13:652-659.
17. Boogaerts MA, Demuynck H: The changing face of stem cell transplantation by the use of recombinant human granulocyte colony stimulating factor. Eur J Cancer 1994, 30A(suppl 3):34-39.
18. Tanaka J, Imamura M, Zhu XF, Kobayashi S, Imai K, Hashino S, Sakurada K, Kasai M, Higa T: Potential benefit of recombinant human granulocyte colony-stimulating factor-mobilized peripheral blood stem cells for allogeneic transplantation. Blood 1994, 84:3595-3596.
19. Nemunaitis J: Overview of the role of hematopoietic growth factors in bone marrow transplant recovery and bone marrow transplant failure. Support Care Cancer 1994, 2:374-376.
20. Schmitz N, Dreger P, Zander AR, Ehninger G, Wandt H, Fauser AA, Kolb HJ, Zumsprekel A, Martin A, Hecht T: Results of a randomised, controlled, multicentre study of recombinant human granulocyte colony-stimulating factor (filgrastim) in patients with Hodgkin's disease and non-Hodgkin's lymphoma undergoing autologous bone marrow transplantation. Bone Marrow Transplant 1995, 15:261-266.
21. Gomez AT, Jimenez MA, Alvarez MA, Rodriguez A, Martin C, Garcia MJ, Flores R, Sanchez J, Delatorre MJ, Herrera C, Roman J, Gomez P, Martinez F: Optimal timing of granulocyte colony-stimulating factor (G-CSF) administration after bone marrow transplantation: a prospective randomized study. Ann Hematol 1995, 71:65-70.
22. Moreau P, Le Tortorec S, Mahe B, Legros L, Millpied N, Harousseau JL: Administration of granulocyte colony-stimulating factor from day 7 after autologous bone marrow transplantation: effects on neutropenia and duration of hospitalizatlon. Nouv Rev Fr Hematol 1994, 36:455-458.
23. Lazarus HM, Rowe JM: Clinical use of hematopoietic growth factors in allogeneic bone marrow transplantation. Blood Rev 1994, 8:169-178.
24. Weisdorf DJ, Verfaillie CM, Davies SM, Filipovich AH, Wagner JE, Miller JS, Burroughs J, Ramsay NKC, Kersey JH, Mcglave PB, Blazer BR: Hematopoietic growth factors for graft faile after bone marrow transplantation: a randomized trial of granulocyte-macrophage colony-stimulating factor (GM-CSF) versus sequential GM-CSF plus granulocyte-CSF. Blood 1995, 85:3452-3456.
25. Demuynck H, Delforge M, Verhoef G, Zachee P, Vandenberghe P, Boogaerts M: Comparative study of peripheral blood progenitor cell collection in patients with multiple myeloma after single-dose cyclophosphamide combined with rhGM-CSF or rhG-CSF. Br J Haematol 1995, 90:384-392.
26. Haas R, Moos M, Karcher A, Möhle R, Witt B, Goldschmidt H, Frühauf S, Flentje M, Wanemacher M, Hunstein W: Sequentlal high-dose therapy with perlpheral-blood progenitor-cell support in low-grade non-Hodgkln's lymphoma. J Clin Oncol 1994, 12:1685-1692.
27. Long GD, Negrin RS, Hoyle CF, Kusnierzglaz CR, Schriber JR, Blume KG, Chao: Multiple cycles of high dose chemotherapy supported by hematopoietic progenitor cells as treatment for patients with advanced malignancies. Cancer 1995, 76:860-868.
28. Dunlop DJ, Fitzsimons EJ, McMurray A, Morrison M, Kyle E, Alcorn MJ, Steward WP: Filgrastim falls to improve haemopoietic reconstitution following myeloablative chemotherapy and peripheral blood stem cell rescue. Br J Cancer 1995, 70:943-945.
29. Klumpp TR, Mangan KF, Goldberg SL, Pearlman ES, MacDonald JS: Granulocyte colony-stimulating factor accelerates neutrophil engraftment following peripheral-blood stem-cell transplantation: a prospective, randomized trial. J Clin Oncol 1995, 13:1323-1327.
30. Dombret H, Chastang C, Fenaux P, Reiffers J, Bordessoule D, •• Bouabdallah R, Mandelli F, Ferrant A, Auzanneau G, Tilly H, Yver A, Degos L: A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia. N Engl J Med 1995, 332:1678-1683. The patients who received lenograstim had a significantly higher rate of complete remission than those who received placebo. However the overall survival in the two groups did not differ significantly.
31. Hiddemann W, Wormann B, Reuter C, Schleyer E, Zuhlsdorf M, Bockmann A, Buchner T: New perspectives in treatment of acute myeloid leukemia by hematopoietic growth factors. Semin Oncol 1994, 21(suppl 16):33-38.
32. Stone RM, Berg DT, George SL, Dodge RK, Paciucci PA, Schulman P, •• Lee EJ, Moore JO, Powell BL, Schiffer CA: Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. N Engl J Med 1995, 332:1671-1677. GM-CSF does not decrease myelosuppressive morbidity or improve the remission rates. Growth factors can not be recommended in elderly patients with acute myelogenous leukemia.
33. Ganser A, Hoelzer D: Treatment of myelodysplastic syndromes with hematopoietic growth factors. Hematol Oncol Clin North Am 1992, 3:633-653.
34. Hellstrom-Lindberg E, Birgegard G, Carlsson M, Carneskog J, Dahl IM, Dybedal I, Grimfors G, Merk K, Tangen JM, Winqvist L: A combination of granulocyte colony stimulating factor and erythropoietin may improve the anemia in patients with myelodysplastic syndromes. Leuk Lymphoma 1993, 11:221-228.
35. Mayordomo JI, Rivera F, Diaz-Puente MT, Lianes P, Colomer R, Lopez Brea M, Lopez E, Paz Ares L, Hitt R, Garcia Ribas I: Improving treatment of chemotherapy-induced neutropenic fever by administration of colony-stimulating factors. J Natl Cancer Inst 1995, 87:803-808.
36. Schimpff SC: Growth factors and empiric therapy with antibiotics: should they be used concurrently? Ann Intern Med 1994, 121:538-540.
37. Bodey GP, Anaissie E, Gutterman J, Vadhan Ray S: Role of granulocyte macrophage colony-stimulating factor as adjuvant treatment in neutropenic patients with bacterial and fungal infection. Eur J Clin Microbiol Infect Dis 1994, 13(suppl 2):18-22.
38. Hardy WD: Combined ganciclovir and recombinant human granulocyte-macroprage colony-stimulating factor in the treatment of cytomegalovirus retinltis in AIDS patients. J Acq Immune Defic Syndr Hum Retrovirol 1991, 4(suppl 1):22-28.
39. Bozzette SA, Parker R, Hay J: A cost analysis of approved antiretroviral strategies in persons with advanced human immunodeficiency virus disease and zidovudine intolerance. J Acquir Immune Defic Syndr Hum Retrovirol 1994, 7:355-362.
40. Vecchiarelli A, Monari C, Baldelli F, Pietrella D, Retini C, Tascini C, Francisci D, Bistoni F: Beneficial effect of recombinant human granulocyte colony-stimulating factor on fungicldal activity of polymorphonuclear leukocytes from patients with AIDS. J Infect Dis 1995, 171:1448-1454.
41. Liang DC, Chen SH, Lean SF: Role of granulocyte colony-stimulating factor as adjunct therapy for septicemla in children with acute leukemia. Am J Hematol 1995, 48:76-81.
42. Russell AR, Davies EG, Ball SE, Gordon-Smith E: Granulocyte colony stimulating factor treatment for neonatal neutropenia. Arch Dis Child Fetal Neonat 1995, 72:53-54.
43. Smith WS, Sumnicht GE, Sharpe RW, Samuelson D, Millard FE: Granulocyte colony-stimulating factor versus placebo in addition to penicillin G in a randomized blinded study of gram-negative pneumonia sepsis: analysis of survival and multisystem organ failure. Blood 1995, 86:1301-1309.
44. Rilikonen P, Rahiala J, Salonvaara M, Perkkia M: Prophylactic administration of granulocyte colony-stimulating factor (filgrastim) after conventional chemotherapy in children with cancer. Stem Cells (Dayt) 1995, 13:289-294.
45. Madero L, Munoz A, Deheredia AD, Martinez A, Badell I, Esquembre C, Ramirez M, Otheo E, Olive A, Sastre A, Pardo N: G-CSF after autologous bone marrow transplantation for malignant diseases in children. Bone Marrow Transplant 1995, 15:349-351.
46. Naparstek E: Granulocyte colony stimulating factor, congenital •• neutropenia and acute myeloid leukemia. N Engl J Med 1995, 333:516-518. A concise update on risks and benefits of myeloid growth factor use in congenital neutropenia and their possible role in neoplastic transformation.
47. Imashuku S, Hibi S, Kataoka-Morimoto Y, Yoshihara T, Ikushima S, Morioka Y, Todo S: Myelodysplasia and acute myeloid leukaemia in cases of aplastic anaemia and congenital neutropenia following G-CSF administration. Br J Haematol 1995, 89:188-190.
48. Sprikkelman A, de Wolf JT, Vellenga E: The application of hematopoletic growth factors in drug induced agranulocytosis: a review of 70 cases. Leukemia 1994, 8:2031-2036.
49. Demuynck H, Zachee P, Verhoef GE, Schetz M, Van den Berghe G, Lauwers P, Boogaerts MA: Risks of rhG-CSF treatment in drug-induced agranulocytosis. Ann Hematol 1995, 70:143-147.
50. Hunault M, Dombret H, Gardin C, Rio B, Hermine O, Brice P, Devidas A, Tulure P, Zini JM, Nedellec G, Sutton L, Miclea JM, Derevel T, Dupuy E, Pautier P, Marolleau JP, Delmer A: Hematopoietlc growth factors in drug-induced agranulocytosis. Leukemia 1995, 9:1286-1287.
51. Bacigalupo A, Broccia G, Corda G, Arcese W, Carotenuto M, Gallamini A, Locatelli F, Mori PG, Saracco P, Todeschini G: Antilymphocyte globulin, cyclosporin, and granulocyte colony-stimulating factor in patients with acquired severe aplastic anemia (SAA): a pilot study of the EBMT SAA Working Party. Blood 1995, 85:1348-1353.
52. Izumi T, Muroi K, Takatoku M, Imagawa S, Hatake K, Miura Y: Development of acute myeloblastic leukaemia in a case of aplastic anaemia treated with granulocyte colony-stimulating factor. Br J Haematol 1994, 87:665-668.
53. Moore MAS: Expansion of myeloid stem cells in culture. Semin Hematol 1995, 32:183-200.